ABVC BioPharma, Inc. (ABVC) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
44370 OLD WARM SPRINGS BLVD. FREMONT, CA 94538 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2023 MRQ | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 9/30/2017 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 161 | 5,937 | 4,273 | 144 | 40 | 205 | |||
| Cash and cash equivalents | 85 | 5,829 | 4,273 | 144 | 40 | 205 | |||
| Short-term investments | 76 | 108 | |||||||
| Restricted cash and investments | 1,306 | 737 | |||||||
| Receivables | 856 | 283 | 696 | 334 | 40 | 2,550 | |||
| Inventory, net of allowances, customer advances and progress billings | 26 | ||||||||
| Inventory | 26 | ||||||||
| Prepaid expense | 172 | 77 | 0 | ||||||
| Other undisclosed current assets | 664 | 2,643 | 1,031 | 323 | 16 | ||||
| Total current assets: | 2,987 | 9,625 | 6,173 | 878 | 96 | 2,755 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 1,161 | 1,472 | 1,773 | 524 | ✕ | ✕ | |||
| Property, plant and equipment | 574 | 526 | 515 | 521 | |||||
| Long-term investments and receivables | 1,983 | 933 | 1,191 | 3,365 | |||||
| Due from related parties | 1,141 | ||||||||
| Long-term investments | 842 | 933 | 1,191 | 3,365 | |||||
| Prepaid expense | 135 | 119 | 119 | 135 | |||||
| Deferred income tax assets | 117 | 982 | 1,791 | ✕ | ✕ | ||||
| Other undisclosed noncurrent assets | 2,897 | 41 | 46 | 1,504 | |||||
| Total noncurrent assets: | 6,868 | 4,073 | 5,434 | 6,050 | |||||
| TOTAL ASSETS: | 9,855 | 13,698 | 11,607 | 6,928 | 96 | 2,755 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 2,910 | 1,301 | 23 | 685 | 449 | 24 | |||
| Employee-related liabilities | ✕ | ✕ | 661 | 444 | 24 | ||||
| Accounts payable | 23 | 24 | |||||||
| Accrued liabilities | 2,910 | 1,301 | 5 | ||||||
| Debt | 1,894 | 1,640 | 1,736 | 2,336 | 300 | ||||
| Due to related parties | 636 | 393 | 288 | 426 | 250 | ||||
| Other undisclosed current liabilities | 380 | 358 | 2,797 | 3,367 | 4,569 | ||||
| Total current liabilities: | 5,820 | 3,692 | 4,844 | 6,814 | 5,568 | 24 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 1,125 | 3,957 | 236 | ||||||
| Long-term debt, excluding current maturities | 2,500 | ||||||||
| Liabilities, other than long-term debt | 792 | 250 | |||||||
| Due to related parties | 250 | ||||||||
| Operating lease, liability | 792 | 1,125 | 1,457 | 236 | ✕ | ✕ | |||
| Other undisclosed noncurrent liabilities | 8 | (1,114) | (1,313) | 3 | 27 | ||||
| Total noncurrent liabilities: | 800 | 1,135 | 4,100 | 238 | 277 | ||||
| Other undisclosed liabilities | 4,124 | ||||||||
| Total liabilities: | 6,619 | 4,828 | 8,945 | 7,053 | 5,846 | 4,148 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | 3,099 | 8,844 | 3,438 | (151) | (5,749) | (1,393) | |||
| Common stock | 33 | 29 | 24 | 19 | 214 | 214 | |||
| Treasury stock, value | (9,100) | (9,100) | (9,100) | (9,100) | |||||
| Additional paid in capital | 67,907 | 58,114 | 40,752 | 28,180 | 13,915 | 13,789 | |||
| Accumulated other comprehensive income | 517 | 540 | |||||||
| Accumulated deficit | (54,904) | (38,481) | (25,642) | (15,851) | (19,878) | (15,395) | |||
| Stockholders' equity note, subscriptions receivable | (1,354) | (2,257) | (3,160) | (4,063) | |||||
| Other undisclosed equity, attributable to parent | 565 | 664 | |||||||
| Equity, attributable to noncontrolling interest | 138 | 27 | (776) | 26 | |||||
| Total equity: | 3,236 | 8,870 | 2,662 | (125) | (5,749) | (1,393) | |||
| TOTAL LIABILITIES AND EQUITY: | 9,855 | 13,698 | 11,607 | 6,928 | 96 | 2,755 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 9/30/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 970 | 356 | 483 | 702 | ||||
| Loss on disposition of assets for financial service operations | (270) | (1,169) | (210) | (2,549) | ✕ | |||
| Cost of revenue | (286) | (5) | (19) | (20) | (1) | |||
| Cost of goods and services sold | (1) | |||||||
| Gross profit: | 683 | 351 | 464 | 682 | (1) | |||
| Operating expenses | (15,798) | (12,057) | (8,970) | (4,140) | (1,394) | (3,858) | ||
| Other undisclosed operating income (loss) | 1 | (138) | ||||||
| Operating loss: | (15,114) | (11,706) | (8,506) | (3,459) | (1,394) | (3,996) | ||
| Nonoperating income (expense) | (400) | 495 | (2,308) | (552) | (2,706) | (75) | ||
| Investment income, nonoperating | 135 | 51 | 43 | (0) | 0 | |||
| Gain (loss), foreign currency transaction, before tax | 426 | (3) | 0 | |||||
| Other nonoperating income (expense) | (400) | 22 | 175 | 93 | ||||
| Interest and debt expense | (294) | (227) | (405) | (1) | (156) | (75) | ||
| Loss from continuing operations before equity method investments, income taxes: | (15,809) | (11,438) | (11,219) | (4,011) | (4,255) | (4,146) | ||
| Other undisclosed income from continuing operations before income taxes | 294 | 227 | 405 | 1 | 156 | 75 | ||
| Loss from continuing operations before income taxes: | (15,515) | (11,211) | (10,814) | (4,010) | (4,099) | (4,071) | ||
| Income tax expense (benefit) | (798) | (825) | 220 | 77 | (2) | (1) | ||
| Loss from continuing operations: | (16,312) | (12,036) | (10,594) | (3,933) | (4,101) | (4,072) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (12,036) | (10,594) | (3,933) | (4,101) | (4,072) | ||
| Net loss: | (16,312) | (12,036) | (10,594) | (3,933) | (4,101) | (4,072) | ||
| Net income (loss) attributable to noncontrolling interest | (111) | 12,036 | ||||||
| Other undisclosed net loss attributable to parent | (12,036) | |||||||
| Net loss attributable to parent: | (16,423) | (12,036) | (10,594) | (3,933) | (4,101) | (4,072) | ||
| Other undisclosed net loss available to common stockholders, basic | (803) | |||||||
| Net loss available to common stockholders, diluted: | (16,423) | (12,839) | (10,594) | (3,933) | (4,101) | (4,072) | ||
Comprehensive Income ($ in thousands)
| 3/31/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 9/30/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (16,312) | (12,036) | (10,594) | (3,933) | (4,101) | (4,072) | ||
| Comprehensive loss: | (16,312) | (12,036) | (10,594) | (3,933) | (4,101) | (4,072) | ||
| Comprehensive income (loss), net of tax, attributable to noncontrolling interest | (111) | 12,036 | ||||||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (23) | (12,864) | 704 | 299 | ||||
| Comprehensive loss, net of tax, attributable to parent: | (16,446) | (12,864) | (9,890) | (3,634) | (4,101) | (4,072) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.